Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 14/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675928 | 0.88 | NPC1 (0.39) | CACNA1HCDK2RETPARP1LCK | |
| SCHEMBL16682132 | 0.83 | CCNA2 (0.46) | CDK2RETROCK2 | |
| SCHEMBL18556887 | 0.82 | CYP2D6 (0.48) | CACNA1HCDK2ROCK2CACNA1GCACNA1I | |
| SCHEMBL16682128 | 0.79 | RET (0.39) | RETLCKSRC | |
| SCHEMBL16682130 | 0.78 | STK25 (0.39) | CDK2RETLCKSRCCACNA1I | |
| SCHEMBL16682168 | 0.76 | P2RX7 (0.37) | CDK2RETROCK2LCKSRC | |
| SCHEMBL9921110 | 0.76 | PRKAB2 (0.42) | CDK2RETLCKSRC | |
| SCHEMBL16682113 | 0.75 | CRHR1 (0.38) | CDK2RETLCKSRCCACNA1I | |
| SCHEMBL16682115 | 0.75 | CRHR1 (0.36) | CDK2RETLCKSRCCACNA1I | |
| SCHEMBL16675969 | 0.75 | TRPA1 (0.37) | CACNA1HPARP1ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | CACNA1H 3756/4885CDK2 3048/4885RET 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.